Literature DB >> 28359736

HLA-A, B, DRB1, DQA1, DQB1 alleles and haplotype frequencies in Dene and Cree cohorts in Manitoba, Canada.

Linda A Larcombe1, Leigh Anne Shafer2, Peter W Nickerson3, Andrew M Lodge4, Jodie S Brown4, Leisel C Milligan5, Denise Pochinco6, Lynnette Beaudin7, Brian Arundel6, Jacqueline Wong7, Joe Dantouze8, Lizette Denechezhe8, Pamela H Orr9.   

Abstract

BACKGROUND: First Nations in the Canadian province of Manitoba have disproportionately high rates of epidemic and endemic TB. Gene polymorphisms that modulate HLA Class I and II antigens are among the risk markers for TB, along with other biologic, and social determinants of health. HLA-A, B, DRB1, DQA1, DQB1 were typed in two Manitoba First Nation indigenous groups to identify and compare the frequency of gene polymorphisms that may influence susceptibility or resistance to TB.
METHODS: Participants who self-identified as either Dene or Cree enrolled into the study from two First Nation communities in Manitoba, Canada. Genomic DNA was extracted from blood samples collected with informed consent from Dene (N=63) and Cree (N=42) First Nation study participants. Participants self-reported having treated active TB, treated latent TB or no TB. HLA Class I and II molecules were typed using sequence-specific oligonucleotide (SSO) probes from commercially available kits.
RESULTS: The rates of treated active and latent TB were marginally higher among the Dene than the Cree participants (p=0.112). Class I and II HLA loci were in Hardy-Weinberg equilibrium in both the Dene and Cree groups. In this exploratory analysis of TB and HLA allele frequencies in Dene and Cree cohorts HLA-A*03 and HLA-DQB1*05:03 were significantly associated with TB.
CONCLUSIONS: The high incidence of TB in both Dene and Cree populations in Canada requires both biomedical and socioeconomic prevention and control measures. Among the former, an understanding of HLA diversity among First Nations groups may aid the development of new effective vaccine and therapeutic modalities that depend on the interaction between small molecules and specific HLA epitopes.
Copyright © 2017. Published by Elsevier Inc.

Entities:  

Keywords:  First Nations; Genetics; HLA; Immunity; TB

Mesh:

Substances:

Year:  2017        PMID: 28359736     DOI: 10.1016/j.humimm.2017.03.009

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  5 in total

1.  [Association between HLA-A and HLA-DRB1 allele polymorphisms and susceptibility to tuberculosis in southern Chinese population].

Authors:  Chunxin Liao; Jiahui Yang; Jinli Wang; Xialin Du; Ruining Wang; Shimeng Zhang; Wenting He; Qian Wen; Li Ma
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-01-30

2.  A Dene First Nation's community readiness assessment to take action against HIV/AIDS: a pilot project.

Authors:  Linda Larcombe; Albert McLeod; Sarah Samuel; Jennifer Samuel; Michael Payne; Stephanie Van Haute; Matthew Singer; Laurie Ringaert; Adrienne F A Meyers; Kathi Kinew; Yoav Keynan; Kelly MacDonald; Joe Antsanen; Pamela Orr
Journal:  Int J Circumpolar Health       Date:  2019-12       Impact factor: 1.228

3.  Polymorphisms in the P2X7 receptor, and differential expression of Toll-like receptor-mediated cytokines and defensins, in a Canadian Indigenous group.

Authors:  Catlin Semple; Ka-Yee Grace Choi; Andrea Kroeker; Lizette Denechezhe; Pamela Orr; Neeloffer Mookherjee; Linda Larcombe
Journal:  Sci Rep       Date:  2019-10-02       Impact factor: 4.379

4.  An Integrative Network Approach to Identify Common Genes for the Therapeutics in Tuberculosis and Its Overlapping Non-Communicable Diseases.

Authors:  Aftab Alam; Hala Abubaker Bagabir; Armiya Sultan; Mohd Faizan Siddiqui; Nikhat Imam; Mustfa F Alkhanani; Ahmad Alsulimani; Shafiul Haque; Romana Ishrat
Journal:  Front Pharmacol       Date:  2022-01-27       Impact factor: 5.810

Review 5.  Influence of Genetic Polymorphism Towards Pulmonary Tuberculosis Susceptibility.

Authors:  Murugesan Harishankar; Paramasivam Selvaraj; Ramalingam Bethunaickan
Journal:  Front Med (Lausanne)       Date:  2018-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.